Format

Send to

Choose Destination
Oncotarget. 2015 Sep 15;6(27):23238-48.

Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Author information

1
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.

Abstract

In proliferating cells, mTOR is active and promotes cell growth. When the cell cycle is arrested, then mTOR converts reversible arrest to senescence (geroconversion). Rapamycin and other rapalogs suppress geroconversion, maintaining quiescence instead. Here we showed that ATP-competitive kinase inhibitors (Torin1 and PP242), which inhibit both mTORC1 and TORC2, also suppressed geroconversion. Despite inhibition of proliferation (in proliferating cells), mTOR inhibitors preserved re-proliferative potential (RP) in arrested cells. In p21-arrested cells, Torin 1 and PP242 detectably suppressed geroconversion at concentrations as low as 1-3 nM and 10-30 nM, reaching maximal gerosuppression at 30 nM and 300 nM, respectively. Near-maximal gerosuppression coincided with inhibition of p-S6K(T389) and p-S6(S235/236). Dual mTOR inhibitors prevented senescent morphology and hypertrophy. Our study warrants investigation into whether low doses of dual mTOR inhibitors will prolong animal life span and delay age-related diseases. A new class of potential anti-aging drugs can be envisioned.

KEYWORDS:

Gerotarget; Pathology Section; aging; pan-mTOR inhibitors; rapalogs; rapamycin; senescence

PMID:
26177051
PMCID:
PMC4695114
DOI:
10.18632/oncotarget.4836
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center